Short answer
Prime Medicine, Inc. (PRME) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $6M (up 408.0% year over year) with net income of −$39M.
Q3 2026 key financials · XBRL
- Revenue
- $6M
- +408.0% YoY
- Net income
- −$39M
- +22.8% YoY · +7.3% QoQ
- Operating margin
- -641.6%
- EPS (diluted)
- −$0.22
- +26.7% YoY · +4.3% QoQ
Source: XBRL data from the Prime Medicine, Inc. (PRME) Q3 2026 10-Q on SEC EDGAR. USD.
Prime Medicine, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue: not disclosed; no product sales, collaboration revenue only
- R&D expenses $34.1M vs $44.0M YoY, down $9.9M
- G&A expenses $10.0M vs $11.2M YoY, down $1.2M
- Cash, equivalents and investments $61.2M at September 30, 2026, including restricted cash $74.8M
- Operating cash outflow $120.4M for nine months, with $109.2M investment maturities; November offering added $134.7M net proceeds
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Risk factors remain updated through the June 30, 2026 Form 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prime Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.